EU begins real-time review of experimental drug molnupiravir

The Merck logo is seen at a gate to the Merck Co campus in Rahway, New Jersey, July 12, 2018. REUTERS Brendan McDermid:

Oct 25 Reuters - U.S. drugmaker Merck Co Inc MRK.N said on Monday that the European Union's drug regulator has initiated a real-time review of its experimental COVID - 19 antiviral drug for adults.

Under the procedure, also known as a rolling review, the European Medicines Agency would assess data as soon as it becomes available, instead of waiting for a formal application when all required information has been gathered.

While vaccines are the main weapons against COVID - 19, Merck's experimental pill molnupiravir could be a game-changer after studies showed it could halve the chances of dying or being hospitalised for those most at risk of contracting severe illness.

Ridgeback Biotherapeutics, which is developing Molnupiravir with partner Merck, filed for U.S. emergency use authorization for the drug on Oct. 11. A panel of outside advisers to the U.S. health regulator are now slated to meet late in November to discuss whether to authorize the experimental antiviral pill. Molnupiravir if approved by regulators would be the first COVID - 19 drug administered orally and also the first treatment for mildly ailing patients, whereas existing drugs are mostly used to treat the critically ill.

The drugmaker has a contract with the U.S. government to supply 1.7 million courses of the drug at a price of $700 per course. It also signed supply agreements with countries including Britain, Malaysia and Singapore recently.

An EU official told Reuters earlier in the month that the bloc was also considering signing a supply agreement for the antiviral pill, but would do so only after the company started the process of seeking approval.